The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
August 7, 2023
View Complete Issue         Table of Contents 2019 
Talazoparib (Talzenna) for Prostate Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Talazoparib (Talzenna) for Prostate Cancer (online only)
August 7, 2023 (Issue: 1682)
The oral poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna – Pfizer) has been approved by the FDA for use in combination with the androgen receptor blocker enzalutamide (Xtandi) for treatment of adults with homologous...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Talazoparib (Talzenna) for Prostate Cancer (online only)
Article code: 1682e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.